Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Amgen

Related AMGN
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
FDA approves expanded use for Amgen's Nplate (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Amgen (NASDAQ: AMGN), and raised its price target from $92.00 to $100.00.

Jefferies noted, “AMGN reported ~in-line 3Q12 total product sales and ~10% beat on EPS on lower OpEx; upped FY12 guidance for revenue slightly and EPS by ~4-5% to partly reflect 3Q12 EPS beat. At its reasonable valuation (~12.6x '13 earnings vs. ~15x for peers vs. ~12x for pharma), stable current revenue, some promising products in development, and increasing quarterly cash dividend ($0.36 in 4Q12 from $0.28 in 3Q11), AMGN represents a good value play.”

Amgen closed on Tuesday at $87.32.

Latest Ratings for AMGN

Nov 2018CitigroupMaintainsNeutralNeutral
Oct 2018Morgan StanleyMaintainsOverweightOverweight
Oct 2018Morgan StanleyMaintainsOverweightOverweight

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (AMGN)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

More Losses Expected for Nintendo as Company Lowers Guidance

Star Scientific Announces Successful First Look at the "Flint" CRP Human Study and Provides Updated Report on ASAP Human Thyroid Study